Fasidotril: The first dual inhibitor of neprilysin and ACE

Cardiovascular Drug Reviews

Volumn 18, Issue 1, 2000, Pages 1-24

  Bralet, J ^a,c   Marie, C ^a   Gros, C ^b   Schwartz, J C ^b   Lecomte, J M ^c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b U Neurobiologie Pharmacologie M   (France)

^c Laboratoire Bioprojet   (France)

Author keywords

Angiotensin converting enzyme; Dual inhibitor; Heart failure; Hypertension; Neprilysin

Indexed keywords

ACETORPHAN; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FASIDOTRIL; IODINE 125; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 3 PHENYLPROPYL)LYSYLPROLINE 4 HYDROXYBENZAMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034034295     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00030.x     Document Type: Review

References (54)

1. Barrett GL, Morgan TO, Smith M, Alcorn D, Aldred P. Effect of converting enzyme inhibition on renin synthesis and secretion in mice. Hypertension 1989;14:385-395.
2. Bevan EG, Connell JMC, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
3. Bhoolla KD, Figueroa CD, Worthy K, Bioregulation of kinins: Kallikreins, kininogens and kininases. Pharmacol Rev 1992;44:1-80.
4. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther 1994;270:8-14.
5. Carmel A, Yaron A. An intramolecularly quenched fluorescent tripeptide as a fluorogenic substrate of angiotensin I-converting enzyme and of bacterial dipeptidyl carboxypeptidase. Eur J Biochem 1978;87:265-273.
6. Cavero PG, Margulies KB, Winaver J, Seymour AA, Delaney NG, Burnett JC. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990;82:196-201.
7. Chien YW, Barbee RW, MacPhee AA, Frohlich ED, Trippodo NC. Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am J Physiol 1988;254:R185-R191.
8. Eiskjaer H, Bagger JP, Danielsen H, et al. Attenuated renal excretory responses to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol 1991;33:71-74.
9. Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.
10. Fink CA. Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Exp Opin Ther Patents 1996;6:1147-1164.
11. Fournié-Zaluski MC, Coric P, Turcaud S, et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: Rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 1994;37:1070-1083.
12. Giros B, Gros C, Schwartz JC, et al. Enantiomers of thiophan and acetorphan: Correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects. J Pharmacol Exp Ther 1987;243:666-673.
13. Gros C, Nöel N, Souque A, et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-4214.
14. Hirata Y, Matsuoka H, Hayakawa H, et al. Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rats. Effect of neutral endopeptidase inhibition. Hypertension 1991;17:1025-1032.
15. Kahn JC, Patey M, Dubois-Rande JL, et al. Sinorphan, an orally enkephalinase inhibitor, enhances plasma atrial natriuretic factor in severe congestive heart failure. Lancet 1990;335:118-119.
16. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase 24.11. Biochem J 1993;291:83-88.
17. Koepke JP, Tyier JD, Blehm DJ, Blaine EH.Chronic atriopeptin regulation of arterial pressure in conscious hypertensive rats. Hypertension 1990;16:642-647.
18. Kohzuki M, Hodsman GP, Johnston CI. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol 1989;256:H533-H538.
19. Kosoglou T, Herron JM, Chen R, Given B, Sybertz EJ, Affrime MB. Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation 1990;82:2201.
20. Kurtz A, Della-Bruna R, Pfeilshifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from isolated renal juxtaglomerular cells by a c-GMP mediated process. Proc Natl Acad Sci USA 1986;83:4769-4773.
21. Laurent S, Boutouyrie P, Azizi M, et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and ACE, in rats and humans. Hypertension 2000, in press.
22. LeFrançois P, Clerc G, Duchier J, et al. Antihypertensive activity of sinorphan. Lancet 1990;336:307-308.
23. Margulies KB, Perrella MA, McKinley LJ, Burnett JC. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-1642.
24. Marie C, Mossiat C, Gros C, Schwartz JC, Lecomte JM, Bralet J. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction. Cardiovasc Res 1999;41:544-553.
25. Marie C, Mossiat C, Lecomte JM, Bralet J. Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure. Pharmacology 1998;56:291-296.
26. Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J Pharmacol Exp Ther 1995;275:1324-1331.
27. Mendez RE, Dunn BR, Troy JL, Brenner BM. Modulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. Circ Res 1986;59:605-611.
28. Monopoli A, Forlani A, Ongini E. Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats. J Hypertens 1991;9:S246-S247.
29. Münzel T, Kurz S, Holtz J, et al. Neurohumoral inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86:1089-1098.
30. Naftilan AJ, Oparil S. Inhibition of renin release from rat kidney slices by the angiotensins. Am J Physiol 1978;235:F62-F68.
31. Nazario B, Hu RM, Pedram A, Prins B, Levin ER. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest 1995;95:1151-1157.
32. Northridge DB, Jardine AG, Alabester CT, et al. A novel atriopeptidase inhibitor. Lancet 1989;2:591-593.
33. Obana K, Naruse M, Naruse K, et al. Synthetic rat atrial natriuretic factor inhibitis in vitro and in vivo renin secretion in rats. Endocrinology 1985;117:1282-1284.
34. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7:943-947.
35. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
36. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-412.
37. Pham I, Gonzalez W, El Amrani AF, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993;265:1339-1347.
38. Richard V, Lecomte JM, Thuilliez C. Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase inhibitor, alatriopril, in the dog. Arch Mal Coeur Vaiss 1993;86:1275-1279.
39. Richards AM, Crozier IG, Kosoglou T, et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993;22:119-126.
40. Robi JA, Trippodo NC, Petrillo EW. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin converting enzyme. In: Van Zwieten PA, Greelee WJ, eds. Antihypertensive Drugs. Amsterdam: Harwood Academic Publishers, 1997;113-212.
41. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993;45:87-145.
42. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: Protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci 1990;47:1279-1287.
43. Selye H, Bajuzs E, Grasso S, Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 1960;11:398-407.
44. Seymour AA, Asaad MM, Lanoce VM, et al. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-883.
45. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-465.
46. Skidgel RA, Defendini R, Erdös EG. Angiotensin I converting enzyme and its role in neuropeptide metabolism. In: Turner AJ, ed. Neuropeptides and Their Peptidases. Chishester, England: Ellis-Horwood, 1987;165-82.
47. Smits GJ, McGraw DE, Trapani AJ, Blaine EB. Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters. J Pharmacol Exp Ther 1990;254:176-179.
48. Stergiou GS, Hannah JA, Bevan EG, et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens 1994;12:11.
49. Sweet CS, Emmert SE, Stabilito II, Ribeiro LGT. Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 1987;10:636-642.
50. Sybertz EJ, Chiu PJS, Watkins RW, Vemulapalli S. Neutral metalloendopeptidase inhibition: A novel means of circulatory modulation. J Hypertens 1990;8(Suppl 7):S161-S167.
51. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990;150:1175-1183.
52. Trippodo NC, Fox M, Natarajan V, et al. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-116.
53. Trippodo NC, Gabel RA, Harvey CN, Rogers WL. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 1991;18:308-316.
54. Wollert KC, Studer R, von Bülow B, Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-2467.